AGCM: Avviata istruttoria sul rincaro dei farmaci tumorali di Aspen

Provvedimento qui.

A Nobel Laureate, Darth Vader© and Access to Health: Balancing IP and Competition in the Pharmaceutical Industry

Giovanni Napolitano

World Intellectual Property Organization 

4th December, 2014, 2 p.m.

DEM - Conference Room

Trento University 

Ebolanomics

NewYorker, here.

French Competition Regulator Probes Roche, Novartis on Avastin

Businessweek.com, here.

AGCM sanziona cartello Roche Novartis

Provvedimento qui.

Driving innovation: How stronger laws help bring safer chemicals to market

B. Tuncak, here. 

Saisine d’office pour avis portant sur le secteur de la distribution pharmaceutique

Autorité de la concurrence, Décision n° 13-SOA-01 du 25 février 2013, ici. 

AGCM c. Bayer Cropscience

Cons. Stato Sez. VI, Sent., 29-01-2013, n. 548, qui.

Drug development: Teaching old pills new tricks

TheEconomist.com, here. 

EU Commission enforcement action in pharmaceutical sector following sector inquiry (January 2013 update)

Press Release, here. 

Amici Curiae Professors and AAI on reverse-payment settlements

Here. 

FTC Amicus Brief on Pharmaceutical "Product Hopping"

MYLAN PHARMACEUTICALS, INC., et al., )  v. WARNER CHILCOTT PUBLIC LIMITED  COMPANY, et al., , here.

AU Government launches review of pharmaceutical patents

Ipaustralia.gov.au, here. 

Pfizer: TAR annulla il provvedimento dell'AGCM

Sentenza qui. 

Anti-Competitive Stumbling Stones on the Way to a Cleaner World: Protecting Competition in Innovation without a Market

J. Drexl, here. 

EU Commission sends Statement of Objections on perindopril to Servier and others

Press Release, here. 

The European Commission's Closer Look on the Pharmaceutical Sector - New Development on the Interface between IP and Antitrust Law

S. Baier, here. 

EU Commission sends Statement of Objections to Lundbeck and others for preventing market entry of generic antidepressant medicine ("pay for delay")

Press release, here. See also the July, 16 "pay for delay" ruling delivered by the US Court of Appeals for the Third Circuit in re K-DUR ANTITRUST LITIGATION, here. 

AstraZeneca V. EC — Reflections on the Advocate General’s Opinion

Covington & Burling LLP, here. 

Impacts of Patent Expiry and Regulatory Policies on Daily Cost of Pharmaceutical Treatments: OECD Countries, 2004-2010

E. Berndt and P. Dubois, here.